Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13879MR)

This product GTTS-WQ13879MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13879MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15533MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ9485MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ5738MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ6229MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ9670MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ11894MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ10414MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ5912MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW